Aurinia Pharmaceuticals Inc (AUPH)

After Hours
- Real-time Data
  • Volume:
  • Bid/Ask:
  • Day's Range:
    21.66 - 28.00

AUPH Comments

What is your sentiment on Aurinia Pharmaceuticals Inc?
Market is currently closed. Voting is open during market hours.
You are viewing a single comment thread.
View the full discussion
  • AUPH reported positive data as competitors 'stumble,' says H.C. Wainwright analyst Ed Arce noted that (AUPH) announced that a "supportive interim analysis" of its AURORA 2 study will be presented at EULAR, held June 2-5. The new data will represent the longest-available outcomes data for LUPKYNIS to date for the treatment of lupus nephritis, or LN, said Arce. Meanwhile, competitor Boehringer Ingelheim announced in a poster presentation at EULAR that its anti-CD40 mAb, BI655064, failed to meet its primary endpoint of complete renal response and Eli Lilly (LLY) disclosed in a recent quarterly filing that TULIP-LN1, its Phase 2 study of anifrolumab, also failed to meet its primary endpoint, according to Arce. The analyst, who maintains his 100% odds of approval view for LUPKYNIS in the U.S., keeps a Buy rating and $35 price target on Aurinia shares. AUPH LLY
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.